Azithromycin has been displayed an antiviral property against zika and ebola virus in vitro. It can prevent severe respiratory tract infection in the case of viral infected patients. Gautret group have treated successfully chronic disease patients with long-term hydroxychloroquine medicines with 600 mg per day for 12 to 18 months. As 17 march 2020, a paper reported (Gautret et al., 2020), they are monitored the viral load in the COVID-19 patients with and without receiving drugs for the six days. They have examined a total of 36 patients, 20 hydroxychloroquine-treated patients and 16 control patients. Among hydroxychloroquine-treated patients, six patients received azithromycin with 500 mg on day 1 followed by 250 mg per day for the next four days. At day 6, 100% patients treated with hydroxychloroquine and azithromycin combination have cured comparing with 57% in patients treated with hydroxychloroquin only, and 12,5% in the control group. Finally they found that hydroxychloroquine and azithromycin combination have cured the COVID-19 patients but the drawback of this study is used a very small size of survey.